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Abstract
Chemoradiotherapy, the standard of care for locally advanced nonesmall-cell lung cancer (NSCLC), often fails to
eradicate all known disease. Despite advances in chemotherapeutic regimens, locally advanced NSCLC remains a
difficult disease to treat, and locoregional failure remains common. Improved radiographic detection can identify
patients at significant risk of locoregional failure after definitive treatment, and newer methods of escalating locore-
gional treatment may allow for improvements in locoregional control with acceptable toxicity. This review addresses
critical issues in escalating local therapy, focusing on using serial positron emission tomography-computed tomog-
raphy to select high-risk patients and employing stereotactic radiotherapy to intensify treatment. We further propose a
clinical trial concept that incorporates the review’s findings.
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Magnitude of the Problem
Lung cancer is the second most common cancer in men and
women, but it is the most common cause of cancer death in the
United States. An estimated 225,000 new cases of lung cancer were
diagnosed in 2016.1 Approximately 30% of these patients presented
with locally advanced, but still potentially curable, stage III disease.2
At most, 25% of these patients will be cured.3 Therefore, up to
40,000 potentially curable patients with stage III nonesmall-cell
lung cancer (NSCLC) will die each year.
What Is Known About the Best Treatment for Stage III
NSCLC
Clinical trials of patients with stage III NSCLC have demonstrated
the benefit of chemotherapy and radiation therapy together versus
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(concurrently) as opposed to one following the other (sequentially)
leads to better outcomes.6 However, beyond these general principles,
little more is known about how to optimize treatment for these pa-
tients. Chemotherapeutic regimens and targeted agents that have
slowly increased survival in patients with NSCLC with metastatic
disease have not increased survival in patients with stage III disease.7-
12 Immunotherapy has opened a new treatment avenue in patients
who have metastatic disease, with long term responses seen in a small
subset of patients13; nonetheless, most patients fail treatment.
Ongoing studies are evaluating its efficacy in patients with stage III
disease, but no results are currently available to support its use. In
summary, clinicians have seen little improvement in patient outcomes
with stage III NSCLC in the last 10 to 15 years.
Why Do We Fail to Cure Stage III
NSCLC?
The Problem of Locoregional Control
Chemoradiotherapy is the standard of care for locoregional
control of locally advanced NSCLC, an absolutely necessary step for
curing the patient. However, there is evidence that this modality, by
itself, is not adequate for this task. For example, in the seminal study
RTOG (Radiation Therapy Oncology Group) 06-17, which
compared 2 radiation doses (60 Gy and 74 Gy), 30% to 40% of
patients experienced radiographic evidence of locoregional failure at
2 years, suggesting the persistence of locoregional disease despite
definitive therapy14 (Figure 1). A meta-analysis regarding patterns ofClinical Lung Cancer January 2018 - 17
Figure 1 Pattern of Failure in RTOG (Radiation Therapy
Oncology Group) 06-17, 60-Gy Arm
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Radiotherapy Escalation in Stage III NSCLCfailure reported locoregional failure rates between 31% and 100%
and mediastinal recurrence rates between 4% and 56%.15 However,
all of these studies relied on radiographic findings to determine the
rates of locoregional failure.
Pathologic findings offer more definitive assessments than radio-
graphic ones, and there is accumulating experience in treating patients
with stage III operable disease with neoadjuvant chemoradiotherapy
followed by surgery. In these patients, a pathologic assessment of
response to therapy can be made. Table 1 demonstrates that fewer
than half of patients with operable stage III NSCLC achieved
pathologic locoregional tumor control following chemoradiotherapy.
Higher doses appear to increase control rates,16-21 with 60 Gy
leading to a 35% pathologic complete response rate.20
Historical Attempts to Improve Locoregional Tumor
Control
Increasing the radiotherapy dose with conventional fractionation
would seem to be a logical way to improve locoregional tumor
control. Single-arm studies suggested improvements in survival in
locally advanced NSCLC with higher doses, but the large phase III
study (RTOG 06-17) failed to show improvement using 74 Gy asTable 1 Complete Pathologic Downstaging as a Function of Radiat
Study No. Patients Years Chem
Pisters16 169 1999-2004 3 c
pa
Albain17 164 1994-2001 45
con
Kim18 233 1989-2008 45
con
Eberhardt19 81 2004-2013 45 G
con
Cerfolio20 185 1998-2008 6
Edelman21 40 1994-2000 69.6
Abbreviation: BID ¼ twice a day.
aReassessment performed at 3-4 weeks with surgery after reassessment.
Clinical Lung Cancer January 2018compared with 60 Gy.14 Indeed, the higher radiotherapy dose was
associated with poorer survival, with possible explanations including
increased normal tissue dose (eg, to the heart), worse compliance
with radiotherapy planning specifications, and/or poorer treatment
tolerability. Locoregional control was also numerically worse in the
74 Gy arm, but this difference was not statistically significant. A
recent meta-analysis concluded that dose escalation above 60 Gy
with conventional fractionation did not benefit patients receiving
concurrent chemotherapy.22
Alternative fractionation regimens have been examined, but direct
comparisons to 60 Gy chemoradiotherapy are lacking.23 The ran-
domized trials continuous hyperfractionated accelerated radiotherapy
(CHART) and CHART weekend-less (CHARTWEL), which used
hyperfractionated/accelerated fractionation regimens, showed some
improvement in overall survival relative to radiotherapy alone, but
with increased toxicity.24,25 Interestingly, a multi-institutional study
(RTOG 94-10) demonstrated improved local control with twice
daily chemoradiotherapy to 69.6 Gy compared with daily chemo-
radiotherapy to 60 Gy, but survival was higher in the 60 Gy arm.26
Such accelerated regimens offer a potential benefit over conven-
tionally fractionated dose-escalation regimens by avoiding longer
treatment periods and the potential for tumor repopulation.
Surgical resection has also been evaluated in operable patients but
has not shown a survival benefit after neoadjuvant chemo-
radiotherapy in randomized trials.17,19 However, neither study
reported patterns of failure, so the impact of surgery on locoregional
control is unknown.
The Effect of Locoregional Control on Overall Disease
Control
Treatment failures can be divided into those that stem from
failure to remove or sterilize locoregional disease and those owing to
preexisting occult disease not identified by current staging methods.
In the first case, lack of locoregional disease control leads to death
from local progression and/or subsequent distant site seeding. In the
second case, disease has already disseminated from the primary and/
or regional tumor. In RTOG 06-17, only 20% to 30% of patients
remained disease-free at 2 years,14 with mixed patterns of failure
(Figure 1).ion Dose
oradiation Therapy Interval to Surgery
Pathologic CR,
%
ycles of carboplatin and
clitaxel. No radiation.
3-8 wk 9
Gy with induction and
current chemotherapy
3-5 wk 18
Gy split course with
current chemotherapy
Not reported 22
y BID with induction and
current chemotherapy
3-9 wk (median 5) 33
0 Gy with concurrent
chemotherapy
Not reported 35
Gy BID with concurrent
chemotherapy
3-4 wka 45
Noah S. Kalman et alThese results and the pathologic outcomes showed in Table 1
suggest that lack of locoregional disease control is a large factor in
the poor cure rates currently seen. There are 2 cautions in inter-
preting these results: first, pathologic complete response rates may
underestimate locoregional disease control just as radiographic
findings may over- or underestimate true recurrence rates owing to
pseudoprogression or occult residual disease; second, better staging
could identify occult distant disease as the dominant mode of fail-
ure, limiting the number of patients with stage III disease that are
curable with improved locoregional disease control. Despite these
caveats, locoregional disease control is a prerequisite for cure in these
patients.
A Way Forward
Lack of locoregional control will lead to failure and subsequent
death in nearly 100% of cases. Although attempts to escalate dose
using conventional radiation fractionation have been largely un-
successful, newer methods of escalating locoregional treatment may
allow for improvements in locoregional control with acceptable
toxicity, especially if patients at significant risk of locoregional
failure can be identified.
Critical Issues in Escalating Therapy
In developing a path forward to improve locoregional treatment
for stage III NSCLC, 2 critical issues must be considered: first,
patients at significant risk of locoregional failure must be identified;
second, effective and safe therapy escalation must be administered.
Herein, pertinent data to guide these decisions is reviewed.
Identifying Those at Significant Risk of Locoregional
Failure
Modality of Radiographic Assessment. Positron emission tomogra-
phyecomputed tomography (PET-CT) has emerged as the most
effective imaging modality to evaluate pretreatment disease, with a
reported sensitivity of 77% to 81% and specificity of 79% to 90%
for detecting mediastinal involvement depending on the criterion
used.27 It has been both claimed and disputed that pretreatment
PET-CT findings are prognostic in patients with lung cancer,28-34
with larger and more recent studies failing to demonstrate prog-
nostic value (Table 2). CT-based assessments of pretreatment tumorTable 2 Prognostic Value of Pretreatment PET-CT
Study Publication Year No. Patients
Cerfolio28 2005 315
Borst29 2005 51
Eschmann30 2006 159
Hoang31 2008 214
Machtay32 2013 226
Calais33 2015 39
Ohri34 2015 28
Abbreviations: DFS ¼ disease-free survival; max ¼ maximum; MTV ¼ metabolic tumor volume; OS
SUV ¼ standard uptake value.volume have also demonstrated prognostic value, and pretreatment
magnetic resonance imaging can predict response to therapy.35
However, prognostic information provided by pretreatment scans
does not alter initial therapy, as attempts to escalate initial therapy
have lacked benefit and increased toxicity. More important is
whether serial peritreatment scans can identify those at significant
risk of locoregional failure despite receiving definitive therapy, so
that treatment can subsequently be adapted.
Serial PET-CT imaging has demonstrated prognostic value in
assessing treatment response that is more robust than the data
supporting other radiographic modalities (CT, magnetic resonance
imaging).35-37 Cerfolio et al and others showed that PET-CT per-
formed after neoadjuvant chemotherapy or chemoradiotherapy
predicted pathologic complete response rates.38-40 Similarly, PET-
CT response predicted survival in studies of chemoradiotherapy
with or without subsequent surgery32,41-44 (Table 3). In these re-
ports, patients with greater declines in tumor PET avidity on
posttreatment scans relative to pretreatment scans had improved
disease control outcomes. For the minority of patients that meet
these PET response thresholds after treatment, further therapy may
not be required. However, the majority of patients remain at high
risk of locoregional failure, and serial PET-CT assessment can be
used to identify these patients that are most appropriate for esca-
lation of locoregional therapy.
Timing of Serial Imaging. Studies involving serial PET-CT im-
aging vary widely in their timing, but can be grouped into post-
treatment and intratreatment categories.45 Serial PET-CT roughly 2
weeks following completion of radiation therapy has demonstrated
the ability to predict pathologic response and survival in patients
receiving chemoradiotherapy for stage III NSCLC38-43 (Table 3).
With the exception of Ryu et al,40 these studies assessed the change
in maximum standardized uptake value (SUVmax) on serial scans,
with decreases between 50% and 80% indicating improved prog-
nosis. Repeat PET-CT imaging at longer intervals (2-3 months)
following radiotherapy showed similar results.32,44 Although
discrete cut-offs were examined in these studies, many authors
concluded that decrease in SUVmax can be considered a continuous
variable with larger changes in SUVmax conferring greater benefit in
patient response to treatment.Stage
Definition of
Threshold Prognostic Value
I-IV SUVmax 10 DFS: yes
OS: yes
I-III SUVmax 15 OS: yes
III SUVavg 12 OS: yes
III-IV SUVmax 11.1 OS: no
III SUVmax and SUVpeak OS: no
II-III SUVmax Local relapse: yes
III MTV total >60 cc
MTV lesion >25 cc
DFS: yes
Lesion recurrence: yes
¼ overall survival; PET-CT ¼ positron emission tomography-computed tomography;
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Table 3 Prognostic Value of Posttreatment PET-CT
Study
Publication
Year
No.
Patients Stage Interval Prior Therapy
Subsequent (Planned)
Therapy Definition of Threshold Prognostic Value
Cerfolio38 2004 56 I-III Within 1 mo Chemotherapy or chemoradiotherapy Surgery SUVmax decrease >80% pCR: yes
Cerfolio39 2006 93 III NRc Chemoradiotherapy Surgery SUVmax decrease >75% (primary)
or >50% (LN)
pCR: yes
Ryu40 2002 26 III 2 wk 42 Gy in 1.5 Gy fx BID (10-day break after
21 Gy) with concurrent 5-FU, cisplatin, and
vinblastine
Surgery followed by
12-18 Gy with concurrent
chemotherapy
SUVmean >3 pCR: yes
Eschmann41 2007 70 III 2 wk Weekly carboplatin-paclitaxel  4c/ 45 Gy
in 1.5 Gy fx BID with concurrent weekly
carboplatin-paclitaxel
Surgery SUVmax decrease >80% OS: yes
Pöttgen42 2006 43 III NRa Cisplatin doublet q3wk  3c/ 44-45
Gy in 1.5 Gy fx BID or 2 Gy qd with concurrent
cisplatin doublet
Surgery SUVmax decrease >50% OS: no
ECP: yes
Pöttgen43 2016 124 III NRb Cisplatin-paclitaxel q3wk  3c Chemoradiotherapy 45 Gy in
1.5 Gy fx BID
followed by surgery or radiotherapy
boost
SUVmax decrease >50% OS: yes
PFS: yes
ECP: yes
Machtay32 2013 173 III 14 wk 60 Gy in 2 Gy fx qd with concurrent platinum
doublet  adjuvant chemotherapy
None SUVpeak >3.5 or 5 OS (3.5): no
OS (5): yes
Mac Manus44 2005 88 I-III 70 d 60 Gy in 2 Gy fx qd  concurrent
chemotherapy
None CMR OS: yes
DM: yes
LRF: yes
Abbreviations: BID ¼ twice a day; CMR ¼ complete metabolic response; DM ¼ distant metastases; ECP ¼ extracerebral progression; fx ¼ fractions; 5-FU ¼ fluorouracil; LRF ¼ locoregional failure; max ¼ maximum; OS ¼ overall survival; pCR ¼ pathologic complete response;
PET-CT ¼ positron emission tomography-computed tomography; PFS ¼ progression-free survival; qd ¼ once a day; q3w ¼ once every 3 weeks.
aAverage interval of 83 days from start of neoadjuvant therapy to follow up PET-CT, suggesting no interval after completion of therapy.
bAverage interval of 57 days from the start of neoadjuvant therapy to follow up PET-CT, suggesting a w2-week interval after the start of the final chemotherapy cycle.
cTiming of post-neoadjuvant therapy PET-CT not known, but presumed to be within 1 month per prior studies from the same group.
Adapted from van Loon et al.45
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Table 4 Prognostic Value of Mid-treatment PET-CT
Study
Publication
Year
No.
Patients Stage
Timing of
PET-CT Therapy
Subsequent
(Planned)
Therapy
Definition of
Threshold Prognostic Value
Toma-Dasu46 2015 27 III Week 2 of
radiotherapy
Cisplatin-
gemcitabine  3c/
79.2 Gy in 1.8 Gy fx
qd OR cisplatin-
vinorelbine  1c/
45 Gy in 1.5 Gy fx
BID then 2 Gy fx qd
up to 69 Gy with
concurrent cisplatin-
vinorelbine
None Average change in
SUV per dose
delivered (continuous
variable)
OS: yes
Usmanij47 2013 28 III Beginning week 3
of radiotherapy
66 Gy in 2 Gy fx qd
with concurrent
cisplatin-etoposide 
lobectomy
None TLG decrease >38% PFS: yes
Yossi48 2015 31 II-III After 30 Gy 66-70 Gy in 2 Gy fx
qd with concurrent
platinum doublet
None TLG decrease >15% OS: yes
PFS: yes
Huang49 2011 37 III-IV After 40 Gy 40 Gy in 2 Gy fx qd
with concurrent
cisplatin doublet then
1.4 Gy fx BID up to
62.4-68 Gy
Adjuvant
cisplatin doublet
X 2-4c
SUVmax decrease
MTV
CT response 4 weeks
post-tx: yes
Zhang50 2011 46 III After 40-50 Gy 60-65 Gy in 1.8-2
Gy fx qd with
concurrent cisplatin
doublet  adjuvant
chemotherapy
None SUVmax decrease
>50%
OS: yes
Kong51 2007 15 I-III After 45 Gy 60þ Gy in 2þ Gy
fx qd  concurrent
and adjuvant
carboplatin-paclitaxel
None CMR CT response: yes
Huang52 2015 53 III After 40 Gy 40 Gy in 2 Gy fx qd
with concurrent
cisplatin doublet then
1.4 Gy fx BID up to
62.4-76.4 Gy
2-4c adjuvant
cisplatin doublet
MTV decrease
>29.7%
LRFS: yes
Abbreviations: BID ¼ twice a day; fx ¼ fraction; LRFS ¼ local relapse-free survival; MTV ¼ metabolic tumor volume; OS ¼ overall survival; PFS ¼ progression-free survival; qd ¼ once a day;
TLG ¼ total lesion glycolysis.
Adapted from van Loon et al.45
Noah S. Kalman et alIntratreatment serial PET-CT offers the ability to adapt therapymid-
treatment, but data supporting this timing is limited to small series. In
patients undergoing thoracic radiotherapy or chemoradiotherapy,
decreases in overall tumor activity (not SUVmax) 2 to 3 weeks into
treatment correlated with overall survival and/or progression free
survival.46-48 Series examining PET-CT changes 4 to 5 weeks into
chemoradiotherapy treatment also appeared to stratify responders and
nonresponders,49-52 but only one study showed an association of PET-
CT changes with survival,50 and these studies differed significantly in
their benchmarks to evaluate PET-CT response. Table 4 summarizes
these results. The current multi-institutional study RTOG 11-06 uses
PET-CT at 5 weeks to identify tumor lesions amenable to dose esca-
lation, with the treatment dose based on retrospective data.53 However,
this approach has not been definitively proven.
There have been concerns that areas of radiotherapy-induced
inflammation, which are fluorodeoxyglucose (FDG)-avid, can
limit the diagnostic accuracy of serial PET-CT imaging in the
peritreatment period. However, these concerns are not substantiated
in published reports. Quantitative assessments of lung parenchymaPET avidity 3 months after radiotherapy show minor changes from
baseline in normal lung tissue relative to large changes from baseline
in lung tumors.54 In one study, radiotherapy-induced inflammatory
lung changes were actually lower on intratreatment PET-CT scans
compared with 3-month PET-CT scans.51
In light of the data supporting early response assessment after
completion of initial therapy, serial scans at roughly 2 weeks post-
treatment appear to allow identification of patients appropriate for
immediate therapy escalation. This small break limits the degree of
tumor repopulation, consistent with timing of surgery in most
protocols with neoadjuvant chemoradiotherapy.17,19 Tumors often
shrink during and immediately following radiotherapy,55 so a small
break provides the additional benefit of treating a smaller target.
Furthermore, the data supporting this approach is more robust than
that supporting intratreatment assessment.
Criteria for Determining Likelihood of Residual Disease. Of the
studies that evaluated response to therapy with PET-CT early
following completion of chemoradiotherapy, a decrease in SUVmax ofClinical Lung Cancer January 2018 - 21
Table 5 Series of SBRT Following Chemoradiotherapy
Study
Publication
Year
No.
Patients Initial Therapy
Subsequent Boost
Therapy Target Timing of Boost Boost Criteria
Median
Follow-up,
mo Outcomes
Feddock61 2013 35 60 Gy chemoradiotherapy
with platinum doublet
10 Gy  2 fx (peripheral)
or 6.5 Gy  3 fx
(medial)
Residual disease þ
1-cm cranio-caudal,
0.5-cm radial expansion
Median time to
completion of SBRT 2
mos after initial treatment
Residual disease 5 cm
on PET-CT w1 mo after
chemoradiotherapy without
nodal or distant disease
13 LC 1 y: 83%
Gr 3 RP: acute 11%,
late 3%
Gr 2 þ RP: acute 17%,
late 9%
2 Gr 5 pulmonary
hemorrhagea
Karam62 2013 16 50.4 Gy
chemoradiotherapy
5 Gy  5 fx Residual disease on
CT þ 0.5-cm expansion
Median 20 d after initial
treatment
All patients received
boost to primary  LNs
14 OS 1 y: 78%
PFS 1 y: 42%
LC 1 y: 76%
RC 1 y: 79%
DC 1 y: 71%
Gr 2 acute RP: 25%
Hepel63 2016 12 50.4 Gy
chemoradiotherapy with
platinum doublet
8-14 Gy  2 fx (42%
also received adjuvant
chemotherapy)
Residual disease þ
0.5-cm expansion
1-4 wk after initial treatment Primary tumor <120 cc,
nodal volume <60 cc
15.5 LC 1 y: 78% (60% if <24
Gy; 100% if 24 Gy)
OS 1 y: 67%
No Gr 3 RP
1 Gr 5 toxicityb
Trovo64 2014 17 50-60 Gy
chemoradiotherapy
30 Gy in 5-6 fx Residual disease þ
0.5-cm expansion
Median 18 mo after
initial treatment
In field recurrent or
persistent central tumor
on PET-CT
18 LC 1 y: 86%
DM 1 y: 47%
OS 1/2 y: 59%/29%
Gr 3 þ RP: 35%
2 Gr 5 toxicityc
Abbreviations: DM ¼ distant metastasis; fx ¼ fraction; LC ¼ local control; LM ¼ lymph node; OS ¼ overall survival; PET-CT ¼ positron emission tomography-computed tomography; PTV ¼ planning target volume; RP ¼ radiation pneumonitis; SBRT ¼ stereotactic body
radiation therapy.
aOccurred at 9 and 10 months after SBRT boost. Both had developed cavitary recurrences involving the hilum; in 1 case, the hilum was included within the high-dose PTV.
bBronchopulmonary hemorrhage 13 months after SBRT boost; patient had received 12 Gy  2 fx. On review, dose to the proximal bronchovascular tree was higher than all other patients.
cOne with pneumonitis 4 months after SBRT, one with hemoptysis 2 months after SBRT.
R
adiotherapy
E
scalation
in
Stage
III
N
SC
L
C
22 -
ClinicalLung
Cancer
January
2018
Noah S. Kalman et al> 50% to 80% was used to predict both residual disease and overall
survival.38,39,41-43 Recent updated PET-CT guidelines use PET
response criteria in solid tumors (PERCIST) criteria to evaluate tu-
mor response to therapy.56 Complete metabolic response is defined as
“complete resolution of FDG uptake within measurable target lesion
so that it is less than mean liver activity and indistinguishable from
surrounding background blood-pool levels.” In effect, any residual
FDG uptake is suspicious for persistent disease. This definition
conforms fairly well to thresholds used in surgical series38-40 and can
be used to identify high-risk patients.
Escalating Locoregional Therapy
Mode of Escalation. Having identified patients at high risk for loco-
regional failure following chemoradiotherapy, possible interventions
can be considered. Surgery has been amainstay of therapy for stage III
NSCLC for many years.17,19,20,41 However, most patients are inop-
erable, even after initial therapy, owing to comorbidities or tumor
location. In a recent nonrandomized study, RTOG 02-29, only
two-thirds of operable patients underwent surgery after chemo-
radiotherapy, with 15% developing significant postoperative
complications.57 Therefore, other options are needed.
Stereotactic body radiotherapy (SBRT) has gained prominence in
lung cancer owing to its effectiveness in treating early stage lesions.58
With SBRT, a higher biologically effective dose (BED) is delivered
relative to conventionally fractionated radiotherapy, with an accepted
threshold dose of 100 Gy in lung cancer.59 Such high doses delivered
in short time periods have the potential to provide better tumor control
above the limited effects seen in conventionally fractionated dose
escalation regimens for stage III NSCLC.22 Several institutions have
taken the tools of lung SBRT and applied them to locally advanced
disease.60 Four prospective studies have examined SBRT to boost
residual disease or treat isolated recurrences61-64 (Table 5). In these
studies, the total delivered BED ranged between 100 and 150 Gy.
In the largest study, Feddock et al delivered a SBRT boost to 35
patients immediately following the completion of chemo-
radiotherapy to 60 Gy. The boost target was defined by the residual
disease seen on PET-CT performed roughly 1 month after
completing initial therapy. Patients with residual primary tumors >
5 cm or residual nodal disease were excluded. The initial boost dose
was 20 Gy in 2 fractions, but after 2 grade 5 toxicities, the dose for
central lesions was modified to 19.5 Gy in 3 fractions.61 Karam et al
delivered a SBRT boost of 20 to 30 Gy in 5 fractions after an initial
50.4 Gy of chemoradiotherapy. Boost treatment started within a
month after completion of initial therapy, and the target volume
included involved mediastinal lymph nodes. No grade 3 to 5
toxicity was observed in this cohort.62 In a recently published dose-
escalation study, Hepel et al provided a SBRT boost after 50.4 Gy
chemoradiotherapy. The SBRT boost, which targeted the residual
primary tumor and lymph nodes, was escalated in 4 Gy increments
from 16 Gy to 28 Gy in 2 fractions (3 patients per dose level).
Interestingly, patients who received 24 or 28 Gy had 100% local
control at 1 year compared with 60% in the patients treated to 16
and 20 Gy. One grade 5 toxicity occurred in a patient treated to 24
Gy with high dose delivered to the proximal bronchovascular tree.
However, toxicity in the remaining patients was limited.63
Other methods of dose escalation that use modestly hypo-
fractionated radiotherapy are under examination (RTOG 11-06),although results are not yet available. Different radiotherapy mo-
dalities such as proton therapy and carbon ion therapy have also
been explored in treating lung cancer, and may offer improved
dosimetry relative to photons,65 although their availability is
limited. Interventions such as radiofrequency ablation have been
tested in early stage lung cancer, but studies comparing radio-
frequency ablation with SBRT found SBRT to be superior.66
Immunotherapy, now commonly used in the metastatic setting,
has been proposed for adjuvant treatment in patients with stage III
disease after chemoradiotherapy.67 Interestingly, the combination of
SBRT and immunotherapy may have a synergistic effect. Multiple
reports have shown that SBRT can potentiate the effect of immu-
notherapy across multiple tumor types, including NSCLC.68 Data
is limited to patients with metastatic disease, but further investiga-
tion may show that combination therapy offers better locoregional
and distant disease control than either alone.
Multiple series across different institutions have documented the
feasibility of lung SBRT after chemoradiotherapy. SBRT, whether
using photons or heavy particles, has been shown to be feasible
across patients with varying degrees of comorbidities and appears to
be the optimal method to escalate therapy. Further study is required
to consider combining radiotherapy and immunotherapy.
Target Definition for SBRT. Primary Versus Lymph Nodes
There is some debate whether the primary tumor is the only site
that requires dose escalation or whether involved lymph nodes are
also at significant risk. The lower volume of disease in lymph nodes
is more likely to be cleared with lower doses of radiation relative to
the larger primary sites.69 However, the pattern of recurrence in
stage III NSCLC is both local and regional.15 Limited series have
demonstrated that PET-CT detects residual nodal disease after
chemoradiotherapy.39 In addition, the study RTOG 02-35
demonstrated that residual PET avidity in lymph nodes indepen-
dently predicted for locoregional failure.70 These results support the
treatment of all residual disease, whether it involves the primary
tumor or mediastinal lymph nodes.
Correlation of PET Avidity and Residual Tumor
PET-avid areas represent sites with the highest likelihood of
harboring residual tumor. However, PET avidity is an imperfect
representation of tumor presence, as hypoxic or necrotic tumor
volumes may demonstrate little FDG uptake despite the presence of
viable cells, and nonetumor-bearing areas can appear PET-avid.71
As residual PET avidity is associated with poorer outcomes, 2
current studies utilize FDG uptake to direct boost therapy (RTOG
11-06 and a Dutch study)72 for increased dose deposition.
Concern for Microscopic Disease at Residual Disease Sites
In delineating targets in stage III NSCLC, radiation oncologists
expand the target beyond the gross target volume (GTV) to ensure
coverage of microscopic disease extension, with the expansions
related to histology and location of disease. However, typically no
target expansion is performed in lung SBRT, with the rationale that
disease extension is more limited at early stages and that the in-
termediate radiation dose received by the tissue surrounding the
target volume is sufficiently high to eradicate microscopic disease. In
patients that have already received full-dose chemoradiotherapy with
target expansions to address microscopic disease, expanding the
SBRT boost target would be unlikely to increase tumor control.Clinical Lung Cancer January 2018 - 23
Figure 2 Protocol Schema
Abbreviations: CMR ¼ complete metabolic response; fx ¼ fractions; PET-CT ¼ positron emission tomography-computed tomography; SBRT ¼ stereotactic body radiation therapy.
Radiotherapy Escalation in Stage III NSCLC
24 -Therefore, limiting the boost target to the volume of residual PET
avidity will likely reduce toxicity without sacrificing disease control.
Normal Tissue Tolerance. Organs at Risk
Established dose constraints for thoracic radiotherapy exist for both
conventionally fractionated radiation and SBRT. Organs at risk
include the lung, spinal cord, chest wall, esophagus, heart, great ves-
sels, brachial plexus, and large and small airways. Treating tumors
adjacent to large airways with SBRT has generated particular concern,
with multiple publications reporting increased toxicity when treating
lesions surrounding the proximal bronchovascular tree.59,73-75
Indeed, grade 5 toxicities in patients receiving a SBRT boost after
chemoradiotherapy were associated with central lesions.61,62 RTOG
08-13, a dose-finding study that examined SBRT specifically for early
stage lesions abutting the proximal bronchovascular tree and/or
mediastinum, reported that treatment was safe and effective,76
although grade 5 toxicities occurred. Overall, the study’s dose con-
straints appear to be a reasonable starting point, with BED conver-
sions used to estimate the combined effect of conventionally
fractionated radiotherapy and SBRT.
After dose constraints are established, various methods can be
employed to help meet these constraints. Active breath hold or
respiratory gating can limit the area of irradiated lung tissue if pa-
tients can tolerate these measures. Image guidance with cone-beam
CT would be mandatory to reduce required treatment margins.77
Mediastinal or central targets would likely require that setup pri-
ority be given to critical structures to reduce the risk of treatment
toxicity.
Boost Dose
The necessary dose to treat early stage lesions is well established at
> 100 Gy BED,59 but the effect of combining conventional and
hypofractionated radiation is less known, as is the effect of a 4- to 6-
week treatment break. Most protocols set a target dose, and if
treatment plans cannot sufficiently spare normal tissue, those pa-
tients are excluded from the study. Another method that has
increased in frequency is to set normal tissue constraints and escalate
dose to the target until these constraints are reached. Indeed, dif-
ferential doses could be given to mediastinal and primary tumor
sites in a given patient to limit dose to the proximal bronchovascular
tree. Because the effect of combining conventionally fractionatedClinical Lung Cancer January 2018radiotherapy with SBRT is not known, a dose-escalation study
design has the added benefit of establishing dose thresholds for
disease eradication and normal tissue toxicity. Although toxicity will
likely be higher in these patients, escalating dose is necessary given
the near certainty of death without further treatment.
Clinical Trial Concept
We propose a clinical trial concept that builds on the ideas dis-
cussed in this article (Figure 2). In patients with stage IIIA to B
NSCLC, initial treatment would consist of the standard arm of
RTOG 06-17, which was radiation with 60 Gy in 30 daily fractions
with concurrent weekly chemotherapy carboplatin and paclitaxel.
Intensity-modulated radiation therapy planning would be preferred to
increase treatment conformality. A baseline PET-CT would be ob-
tained prior to starting chemoradiotherapy, as is commonly done for
routine staging. Pathologic confirmation would be required through
sampling of an involved lymph node station or primary tumor.
Roughly 2 weeks following the completion of chemo-
radiotherapy, a repeat PET-CT would be performed. At this point,
patients would be separated into 3 groups: (1) patients with com-
plete metabolic response to all sites of disease by PERCIST criteria;
(2) patients without complete metabolic response with residual
disease not amenable to SBRT; and (3) patients without complete
metabolic response but with residual disease amenable to SBRT.
Patients with complete metabolic response would not receive
additional therapy. Patients without complete metabolic response
and not amenable to SBRT would receive systemic therapy at the
treating oncologists’ discretion and would be restaged at a later date
for consideration of SBRT if disease regressed sufficiently.
Patients with residual disease amenable to SBRT would undergo
resimulation and receive SBRT (heavy particle therapy would be
allowed if available). Treatment would consist of 5 fractions deliv-
ered over 2 weeks with a minimum dose per fraction of 5 Gy
marginal dose (cumulative dose w110 Gy BED). If normal tissue
constraints are met, the dose can be escalated up to 10 Gy per
fraction, which would represent 100 Gy BED not including the
initial course of chemoradiotherapy.
The primary treatment outcome would be progression-free sur-
vival at 24 months. Progression would be defined by PERCIST
criteria for progressive disease (> 25% increase in SUV from
Noah S. Kalman et alposttreatment imaging or presence of new FDG-avid lesions). Sec-
ondary outcomes would include time to locoregional and distant
failure, overall survival, and acute and late treatment toxicity. Criteria
for early stopping would be significantly increased development of
grade 4/5 toxicity relative to historical series. Because the patients that
receive SBRT would represent a higher risk population than an un-
selected stage III cohort, the benchmark for trial success would be to
match the 20% to 30% progression-free survival at 24months seen in
RTOG 06-17 in this group.
A Call to Arms
We challenge the thoracic oncology community to contact the
authors to assist with designing a comprehensive protocol and to
submit for institutional funding. Stage III lung cancer has stub-
bornly resisted efforts to improve control rates in the past 10 to 15
years. With new diagnostic and treatment tools, progress can be
made in this aggressive but curable disease.
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